TLX vs. RPRX, BGNE, UTHR, SMMT, GMAB, VTRS, ITCI, INSM, RDY, and BMRN
Should you be buying Telix Pharmaceuticals Limited American Depositary Shares stock or one of its competitors? The main competitors of Telix Pharmaceuticals Limited American Depositary Shares include Royalty Pharma (RPRX), BeiGene (BGNE), United Therapeutics (UTHR), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Insmed (INSM), Dr. Reddy's Laboratories (RDY), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "pharmaceutical preparations" industry.
Telix Pharmaceuticals Limited American Depositary Shares vs.
Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
In the previous week, Telix Pharmaceuticals Limited American Depositary Shares and Telix Pharmaceuticals Limited American Depositary Shares both had 3 articles in the media. Royalty Pharma's average media sentiment score of 1.09 beat Telix Pharmaceuticals Limited American Depositary Shares' score of 0.37 indicating that Royalty Pharma is being referred to more favorably in the news media.
Royalty Pharma has higher revenue and earnings than Telix Pharmaceuticals Limited American Depositary Shares.
Royalty Pharma has a net margin of 50.53% compared to Telix Pharmaceuticals Limited American Depositary Shares' net margin of 0.00%. Royalty Pharma's return on equity of 24.65% beat Telix Pharmaceuticals Limited American Depositary Shares' return on equity.
Telix Pharmaceuticals Limited American Depositary Shares presently has a consensus target price of $21.00, indicating a potential upside of 24.56%. Royalty Pharma has a consensus target price of $41.67, indicating a potential upside of 37.51%. Given Royalty Pharma's higher probable upside, analysts clearly believe Royalty Pharma is more favorable than Telix Pharmaceuticals Limited American Depositary Shares.
54.4% of Royalty Pharma shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Royalty Pharma received 322 more outperform votes than Telix Pharmaceuticals Limited American Depositary Shares when rated by MarketBeat users. However, 100.00% of users gave Telix Pharmaceuticals Limited American Depositary Shares an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote.
Summary
Royalty Pharma beats Telix Pharmaceuticals Limited American Depositary Shares on 10 of the 12 factors compared between the two stocks.
Get Telix Pharmaceuticals Limited American Depositary Shares News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telix Pharmaceuticals Limited American Depositary Shares Competitors List
Related Companies and Tools
This page (NASDAQ:TLX) was last updated on 1/22/2025 by MarketBeat.com Staff
